Refining intermediate-risk (IR) stratification in patients (Pts) with metastatic renal cell carcinoma (mRCC) receiving first-line (1L) immunotherapy (IO) within one year of diagnosis (Dx): Findings from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Razane El Hajj Chehade(Dana-Farber Cancer Institute), Toni K. Choueiri(Harvard University), Eddy Saad(Dana-Farber Cancer Institute), Rashad Nawfal(Dana-Farber Cancer Institute), J. Connor Wells(Queen's University), Sumanta K. Pal(City of Hope), Wassim Daoud Khatoun(Dana-Farber Cancer Institute), Sylvan C. Baca(Broad Institute), Karl Semaan(Broad Institute), Kosuke Takemura(Japanese Foundation For Cancer Research), Wanling Xie(Dana-Farber Cancer Institute), Marc Machaalani(Dana-Farber Cancer Institute), Cristina Suárez(Complejo Hospitalario de Salamanca), Clara Steiner(Dana-Farber Cancer Institute), Emre Yekedüz(Dana-Farber Cancer Institute), Marc Eid(Harvard University), Daniel Yick Chin Heng(University of Calgary), Martín Zarbá(University of Calgary), Haoran Li, David Maj(University of Calgary)
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k